NCT03685331
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy, Misc Inhibitor
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have germline or somatic BRCA mutation; Prior treatment with 0-2 prior lines of chemotherapy for MBC- see trial for details
Exclusions: Patients with symptomatic uncontrolled brain metastases; Patients who have had prior treatment with a PARP inhibitor or CDK4/6 inhibitor
https://ClinicalTrials.gov/show/NCT03685331